@article{article, title  = {{Abstract CT119: A first-in-human phase 1 study of LOXO-435, a potent, highly isoform-selective FGFR3 inhibitor in advanced solid tumors with <i>FGFR3</i> alterations (trial in progress)}},

 publisher = {{American Association for Cancer Research (AACR)}},

 url = {{http://dx.doi.org/10.1158/1538-7445.am2023-ct119 }},

 year = {{2023}},

 month = {{4}},

 author = {{Iyer G and Siefker-Radtke A and Milowsky M and Shore N and Gao X and Reimers MA and Hahn N and Cosman R and Matsubara N and Necchi A and Robbrecht D et al}},

 doi = {{10.1158/1538-7445.am2023-ct119}},

 volume = {{83}},

 journal = {{Cancer Research}},

 issue = {{8_Supplement}},

 pages = {{CT119-CT119}},

 note = {{Accessed on 2024/12/21}}}